The AdvanceGxP service, funded by the Office for Life Sciences (OLS), will assist companies developing novel manufacturing technologies, including personalised treatments, space-based manufacturing, and the application of AI, robotics, and automation. The goal is to help innovators address regulatory and quality challenges early in the development process, thereby reducing the risk of delays and redesigns.
MHRA Chief Executive, Lawrence Tallon, stated, "We want the UK to be a place where the next generation of innovative medicines can be developed and made. Giving developers practical support earlier can help solve problems before they cause delays, build confidence to invest and make it easier for promising new approaches to grow and scale here."
OLS Director, Kenan Poleo, added, "By helping regulation keep pace with innovation, AdvanceGxP will give companies greater confidence to develop and manufacture transformative new technologies here in the UK."
The funding will allow the MHRA to establish a specialist team to develop the service, defining access methods, prioritisation criteria, and integration with existing MHRA support structures. Initial capacity will be limited during the development and testing phase.
This initiative aligns with the MHRA Strategy to 2030 and broader government ambitions to enhance the UK's life sciences and advanced manufacturing sectors. The announcement was made at the inaugural DIA-MHRA Global Summit, a joint event by the MHRA and the Drug Information Association (DIA) focused on international collaboration for innovation.




